Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fish and Richardson
Baxter
Harvard Business School
Daiichi Sankyo
Johnson and Johnson
Argus Health
Cerilliant
Merck

Generated: October 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021711

« Back to Dashboard

NDA 021711 describes ABLAVAR, which is a drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ABLAVAR profile page.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.
Summary for 021711
Tradename:ABLAVAR
Applicant:Lantheus Medcl
Ingredient:gadofosveset trisodium
Patents:1
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 021711
Generic Entry Date for 021711*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength2440MG/10ML (244MG/ML)
Approval Date:Dec 22, 2008TE:RLD:No
Patent:➤ Sign UpPatent Expiration:May 4, 2020Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength3660MG/15ML (244MG/ML)
Approval Date:Dec 22, 2008TE:RLD:No
Patent:➤ Sign UpPatent Expiration:May 4, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021711

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Deloitte
Merck
Mallinckrodt
Federal Trade Commission
Julphar
US Department of Justice
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.